Mankind Pharma Ltd (MANKIND)
🎯 Key Takeaways
- Mankind Pharma is undergoing a strategic consolidation phase, marked by the voluntary liquidation of its 96%-owned subsidiary Bharat Serums and Vaccines Limited (BSVL) to streamline operations and reduce compliance costs. The company is also executing leadership transitions, including the completion of Independent Director Bharat Anand's term and the proposed appointment of Anish Vanraj Bafna as a new independent director pending shareholder approval.
- Revenue grew 17.1% QoQ to ₹4,031 in Q1FY27.
- ⚠️ Execution risk in the BSVL liquidation process under IBC and SEBI regulations could delay consolidation and impact expected efficiency gains.
📖 The Story
Mankind Pharma is undergoing a strategic consolidation phase, marked by the voluntary liquidation of its 96%-owned subsidiary Bharat Serums and Vaccines Limited (BSVL) to streamline operations and reduce compliance costs. The company is also executing leadership transitions, including the completion of Independent Director Bharat Anand's term and the proposed appointment of Anish Vanraj Bafna as a new independent director pending shareholder approval. These moves reflect a broader effort to strengthen governance and operational efficiency amid a challenging market environment, as evidenced by a slight decline in 1Y return and margin pressure in recent quarters.
📰 What's Happening
The board approved the voluntary liquidation of BSVL to consolidate its operations into the parent company, aiming to enhance efficiency and reduce duplicate compliance burdens. The liquidation will be executed under IBC 2016 and SEBI regulations, with Appian receiving a cash payout equivalent to 4% of BSVL's fair value. Additionally, shareholders are being asked to approve the appointment of Anish Vanraj Bafna as a Non-Executive Independent Director via e-voting, with results expected by September 21, 2026. This follows the completion of Bharat Anand's second term on the board, marking a shift in board composition and governance oversight.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 3,697 | 3,567 | 3,443 | 4,031 |
| Operating Profit | 700 | 697 | 707 | 830 |
| OPM % | 18.9% | 19.5% | 20.5% | 20.6% |
| Net Profit | 520 | 414 | 559 | 574 |
| EPS | ₹12.39 | ₹9.90 | ₹13.44 | ₹13.76 |
Revenue has shown a modest upward trend, rising from ₹3,697 crore in September 2025 to ₹4,031 crore in June 2026, while operating profit and net profit have improved sequentially. However, operating margins have remained relatively stable around 19-20.6%, indicating limited pricing power or cost control gains despite revenue growth. Net profit declined sharply in December 2025 to ₹414 crore before recovering to ₹574 crore in June 2026, suggesting volatility in profitability that may be linked to one-time costs or operational fluctuations. The sequential improvement in profitability aligns with management’s focus on operational efficiency through structural consolidation.
🔮 Management Outlook & What's Next
Management has not provided explicit forward guidance on revenue or margin expectations in the latest filings, but has emphasized that the BSVL consolidation is expected to improve operational efficiency, resource utilization, and governance while reducing compliance costs. The liquidation process is underway under regulatory frameworks, with distribution to Appian contingent on approvals and licenses. The company is focused on simplifying its corporate structure, which may enhance cash flow visibility and reduce administrative overhead, though execution risks remain tied to regulatory timelines.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 40 | 41 | 41 | 41 |
| Reserves | 10,525 | 14,291 | 15,245 | 16,259 |
| Borrowings | 482 | 8,511 | 8,369 | 6,204 |
| Total Liabilities | 13,982 | 27,760 | 28,813 | 28,080 |
| Fixed Assets | 2,922 | 2,908 | 2,926 | 19,093 |
| Investments | 3,856 | 2,042 | 2,947 | 1,985 |
| Total Assets | 13,982 | 27,760 | 28,813 | 28,080 |
The balance sheet shows a stable capital structure with equity remaining flat at ₹41 crore, while reserves have increased from ₹14,291 crore to ₹16,259 crore, indicating retained earnings growth. Borrowings have declined from ₹8,511 crore to ₹6,204 crore, suggesting active deleveraging or reduced reliance on debt financing. Total assets have risen modestly, reflecting operational expansion or investment in existing operations. The improving equity-to-asset ratio and declining debt levels signal a strengthening financial position and prudent capital management, supporting greater financial flexibility.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2026 |
|---|---|
| Operating | +3,121 |
| Investing | -196 |
| Financing | -2,953 |
| Net Cash Flow | -28 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 72.7% | 72.7% | 72.7% | 72.6% |
| FII | 12.8% | 11.3% | 10.2% | 9.4% |
| DII | 11.9% | 13.3% | 14.5% | 15.4% |
| Public | 1.4% | 1.5% | 1.4% | 1.3% |
| # Shareholders | 1,70,347 | 1,77,539 | 1,77,606 | 1,66,715 |
Promoter holding has remained stable around 72.6% over the past few quarters, indicating continued confidence from the promoter group. FII ownership has declined slightly from 12.84% to 9.45%, while DII has increased from 11.92% to 15.39%, suggesting growing institutional interest from mutual funds and insurance companies. The rising number of shareholders (1,66,715 to 1,77,606) reflects broadening retail participation. Overall, the shareholding pattern shows a gradual shift toward institutional investors, which may support long-term governance and market liquidity.
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.63 L Cr | 38.3 | 18.7% | 14.6% | 0.05 |
| DIVISLAB | 2.43 L Cr | 83.2 | 23.0% | 17.4% | 0.00 |
| TORNTPHARM | 1.89 L Cr | 79.1 | 15.1% | 25.7% | 1.76 |
| ZYDUSLIFE | 1.16 L Cr | 25.9 | 16.8% | 16.6% | 0.43 |
| CIPLA | 1.15 L Cr | 34.0 | 13.2% | 9.8% | 0.01 |
| LAURUSLABS | 1.00 L Cr | 91.8 | 20.8% | 20.6% | 0.45 |
| LUPIN | 98,305 | 17.4 | 27.9% | 24.7% | 0.26 |
| DRREDDY | 97,741 | 30.3 | 10.1% | 8.4% | 0.17 |
| MANKIND | 97,467 | 47.7 | 13.9% | 12.7% | 0.38 |
| AUROPHARMA | 96,836 | 26.3 | 12.8% | 9.8% | 0.20 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1. Execution risk in the BSVL liquidation process under IBC and SEBI regulations could delay consolidation and impact expected efficiency gains. 2. Margin pressure persists despite revenue growth, with operating margins stagnant, raising concerns about pricing power or cost management. 3. Leadership changes, including the exit of Independent Director Bharat Anand and pending appointment of his successor, may affect board continuity and governance oversight during a transitional phase. 4. The company operates in a highly competitive and regulated pharmaceutical sector, where regulatory changes or patent expiries could impact profitability.
📋 Recent Filings
-
🔴 Corporate Action 1 September 2026Mankind Pharma allotted 49,112 equity shares under its 2022 Employee Stock Option Plan on September 1, 2026, increasing paid-up capital from 41,29,95,...
-
🔴 Announcement 31 August 2026Mankind Pharma announced it has completed the sale of its entire 100% stake in Broadway Hospitality Services Private Limited to AKRK Projects LLP, eff...
-
🟡 Board Meeting 30 August 2026Mankind Pharma announced that Independent Director Bharat Anand completed his second term effective August 30, 2026, and ceased membership from all fo...
-
🟡 Board Meeting 26 August 2026Mankind Pharma announced that its board approved the voluntary liquidation of its 96%-owned subsidiary Bharat Serums and Vaccines Limited (BSVL), enab...
-
🟡 Board Meeting 26 August 2026Mankind Pharma announced the board approved voluntary liquidation of its 96% owned subsidiary Bharat Serums and Vaccines Limited (BSVL) to consolidate...
-
Announcement 22 August 2026Mankind Pharma announced an independent ESG rating of 64 from CRISIL ESG Ratings, up from 57, placing it in the 'Strong' category, with core ESG impro...
-
Announcement 20 August 2026Mankind Pharma announced an exclusive in-licensing agreement with Chongqing Chenan Biopharmaceutical for insulin degludec and insulin degludec + aspar...
-
🟡 voting results 18 August 2026Mankind Pharma Limited announced a postal ballot notice seeking shareholder approval via e-voting for the appointment of Mr. Anish Vanraj Bafna as a N...
-
🔴 Announcement 13 August 2026Mankind Pharma announced the incorporation of its wholly owned subsidiary, Mankind Pharma (Netherlands) B.V., in the Netherlands on August 13, 2026, a...
-
Announcement 10 August 2026Mankind Pharma announced its management will attend three investor conferences in August 2026, including Emkay Confluence, Equirus Annual India Confer...
🧠 Analyst's Read
Mankind Pharma is in a strategic restructuring phase, simplifying its corporate structure through BSVL liquidation and board realignment, while maintaining a stable financial profile with improving reserves and declining debt. Investors should monitor the progress of the BSVL liquidation approvals and the appointment of the new independent director, as these will determine the pace of operational consolidation. The company's ability to sustain profitability amid margin pressure and competitive dynamics will be critical to watch in the coming quarters.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-02.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when MANKIND files new disclosures
Track MANKIND filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track MANKIND — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research
About · Privacy Policy · Terms of Service · Pricing
Today's Announcements · Screener · Insights · AI Chat
Data provided by CMOTS Internet Technologies Pvt Ltd